Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DUSA Pharmaceuticals' Actinic Keratosis PDT Treatment Is Tip Of Pipeline

This article was originally published in The Gray Sheet

Executive Summary

DUSA Pharmaceuticals plans to submit a premarket approval application supplement within the next two months for the commercial version of the firm's BLU-U light source used in conjunction with the Levulan Kerastick actinic keratoses therapy.

You may also be interested in...



DUSA Pharmaceuticals

Maker of Levulan photodynamic therapy and photodetection products receives FDA "approvable" letter for a PMA supplement for a commercial version of its BLU-U light source for use in conjunction with the Levulan Kerastick actinic keratoses therapy for the face and scalp. A BLU-U prototype gained approval in December 1999 in conjunction with a new drug application for Levulan (1"The Gray Sheet" Dec. 13, 1999, p. 17)

DUSA Pharmaceuticals

Maker of Levulan photodynamic therapy and photodetection products receives FDA "approvable" letter for a PMA supplement for a commercial version of its BLU-U light source for use in conjunction with the Levulan Kerastick actinic keratoses therapy for the face and scalp. A BLU-U prototype gained approval in December 1999 in conjunction with a new drug application for Levulan (1"The Gray Sheet" Dec. 13, 1999, p. 17)

Ablation Versus Hysterectomy For Menorrhagia Achieves Cost Savings

Performing endometrial ablation in lieu of hysterectomy for treatment of dysfunctional uterine bleeding (DUB) can provide savings in the managed care setting, according to a recent study published in the American Journal of Managed Care.

Related Content

UsernamePublicRestriction

Register

MT012695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel